There is one clinical trial.
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.
Description: AUC0-tlast of favipiravir obtained by plasma concentration
Measure: AUC0-tlast of favipiravir Time: 0 to 24 hours post-doseDescription: Cmax of favipiravir obtained by plasma concentration
Measure: Cmax of favipiravir Time: 0 to 24 hours post-doseDescription: AUC0-inf of favipiravir obtained by plasma concentration
Measure: AUC0-inf of favipiravir Time: 0 to 24 hours post-doseDescription: tmax of favipiravir obtained by plasma concentration
Measure: tmax of favipiravir Time: 0 to 24 hours post-dose